Which manufacturer is responsible for producing selumetinib?

Selumetinib is an oral small molecule MEK inhibitor that blocks the MAPK/ERK signaling pathway mainly by inhibiting MEK1/2 kinase activity. It is widely used to treat neurofibromatosis and certain types of cancer. The original research and development of this drug was led by the famous British pharmaceutical company AstraZeneca (AstraZeneca). AstraZeneca is one of the world's leading biopharmaceutical companies with deep R&D capabilities in cancer, cardiovascular disease and rare diseases. Later, part of the development and commercialization rights of selumetinib were transferred or jointly developed, especially the cooperation with the field of pediatric oncology in the United States. In particular, its cooperation with the National Cancer Institute (NCI) has promoted its research progress in the field of neurofibromatosis.

Selumetinib was first approved by the US FDA in 2020 for the treatment of symptomatic non-malignant schwannoma associated with neurofibromatosis type 1 (NF1). It is the first and currently the only MEK inhibitor approved for this indication. This approval marks a major breakthrough in the treatment of rare genetic diseases. AstraZeneca is the main global manufacturer and seller of the drug. It has also applied for marketing in the European Union, Japan and other regions, and has been recognized by regulatory agencies in many countries.

In the Chinese market, the launch of selumetinib has also made substantial progress. It has been approved by the original developer and has been officially introduced into the Chinese market for clinical treatment. This initiative fills the domestic drug gap in the treatment of NF1-related diseases. The introduction of the original drug selumetinib into China is a milestone in the field of rare disease treatment and provides a new treatment option for Chinese neurofibromatosis patients.

Reference materials:https://www.koselugo.com